Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases

Spero Therapeutics’ antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal.

Our pipeline of anti-infective agents is one of the most unique in the industry and consists of four product candidates, including:

• SPR994, a first in class oral carbapenem that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacterial infections, including those harboring drug-resistant extended-spectrum beta-lactamases (ESBLs).
• SPR720, an candidate oral antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM) lung infections.
• IV Potentiator Platform includes SPR206 and SPR741, two intravenous (IV)-administered next-generation polymyxin analogues in clinical development as innovative options to treat MDR Gram-negative bacterial infections within the hospital.  The agents have demonstrated broad Gram-negative antibacterial activity as monotherapy (SPR206) or by co-administration with existing antibiotics (SPR741).

The following table illustrates our product candidates, their status, and anticipated milestones for ongoing development.

Product Candidate Pipeline and Anticipated Milestones

Information as of June 1, 2019

This chart contains forward-looking statements. Our planned development activities and anticipated milestones are based on our current assumptions, estimates and plans, which may change.